SPNE - SPNE STOCK NEWS

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced a study published in The Journal of Bone and Joint Surgery showing that cellular bone matrix (CBM) products do not enhance spinal fusion. SeaSpine's demineralized bone matrix (DBM) product, OsteoStrand Plus, outperformed tested CBM products. Conducted by researchers at USC and Emory, the study raises concerns about the high costs of CBMs without proven clinical benefits. This finding reinforces the pushback from payors regarding CBMs, supporting SeaSpine’s differentiated DBM offerings in a competitive market valued at $400-$500 million.

SeaSpine Holdings Corporation (NASDAQ: SPNE) will release its third quarter financial results on November 9, 2020, after market close. A conference call and webcast will follow at 1:30 pm PT / 4:30 pm ET. Interested parties can listen by calling (877) 418-4766 for domestic or (614) 385-1253 for international access, using Conference ID: 3469075. SeaSpine specializes in surgical solutions for spinal disorders and offers a diverse range of orthobiologics and spinal implants aimed at improving surgical outcomes and bone fusion rates.

SeaSpine (NASDAQ: SPNE), a medical technology company, announced that four abstracts featuring its products will be presented at the NASS 2020 Annual Meeting, scheduled virtually. Notably, two abstracts earned the "Best Paper" designation, highlighting their excellence among the 1,234 submissions. The presentations will focus on various aspects of spinal disorder treatment, with content available for registered attendees until March 2021. SeaSpine emphasizes the importance of research and collaboration in advancing the quality of its solutions for spinal fusion procedures.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced preliminary third quarter 2020 financial results, projecting revenues between $42.9 million and $43.3 million, an 8% to 9% increase year-over-year. U.S. revenues are expected to grow 9% to 10%, with spinal implants and orthobiologics revenues increasing by 10-11% and 8-10%, respectively. International revenue is anticipated to decline by 5% to approximately $4.1 million. For Q4 2020, SeaSpine expects revenues of $47.0 to $48.0 million, reflecting 7-10% growth compared to the prior year.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced the issuance of inducement awards to seventeen non-executive employees on October 1, 2020. The awards include options to purchase 11,574 shares and restricted stock units for 21,769 shares of common stock. The exercise price of options is $14.41, equaling the closing price on the grant date. Options will vest fully after one year, while restricted stock units will vest in equal installments over three years. This initiative aligns with Nasdaq Marketplace Rule 5635(c)(4) and aims to attract new talent to SeaSpine.

SeaSpine Holdings Corporation (NASDAQ: SPNE) announced the limited commercial launch of its WaveForm C Interbody Implant System on September 23, 2020. This implant, marking a year since the exclusive licensing agreement with restor3d, is the first of five 3D-printed interbody devices expected by mid-2021. WaveForm C features a highly porous structure designed to enhance surgical efficiency and patient outcomes in anterior cervical spine procedures. The launch expands SeaSpine's cervical portfolio, aligning with its Fusion Engineered philosophy and best-in-class allograft offerings.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a medical technology company specializing in spinal disorder solutions, will present at the Wells Fargo Securities Healthcare Conference on September 10, 2020, at 2:00 pm ET. The event will be accessible via a live and archived webcast on the company's Investor Relations page. SeaSpine is known for its innovative orthobiologics and spinal implants that assist surgeons in spinal fusion procedures. The company operates in the United States and approximately 30 global markets, ensuring a diverse portfolio for healthcare professionals.

SeaSpine Holdings Corporation (NASDAQ: SPNE) has announced the commercial launch of the Shoreline RT Cervical Interbody Implant System, enhancing its NanoMetalene technology with proprietary Reef Topography. This new system boasts a 40% increase in NanoMetalene endplate surface area and 50% increase in aperture surface area compared to previous models. Designed for ACDF procedures, the Shoreline RT system offers multiple footprints and lordotic options, aiming to improve fusion outcomes when used with SeaSpine’s allograft offerings. This aligns with the company's Fusion Engineered philosophy.

SeaSpine Holdings (NASDAQ: SPNE) announced on August 7, 2020, the issuance of inducement awards to eleven non-executive employees. These awards comprise options to purchase 22,753 shares and restricted stock units for 17,832 shares of common stock. The options have an exercise price of $14.82, equivalent to the closing stock price on the grant date, and a term of eight years. Vesting for options occurs in installments beginning after one year, while restricted stock units vest over three years. This initiative aims to attract new talent in compliance with Nasdaq Marketplace Rule 5635(c)(4).